COPD

Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.

Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.

The FDA announced approval of Wixela Inhub on January 30, 2019.

The generic product (Wixela Inhub, Mylan) will be offered in 3 strengths at wholesale acquisition costs that are 70% less than the brand equivalent Advair Diskus, according to Mylan.

With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.

Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.

The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.

Teva has just unveiled the world's first integrated smart inhaler to the market.

Four cases address respiratory illnesses.

A new study indicates that there are age-associated gender differences seen in the disease burden of chronic obstructive pulmonary disorder (COPD), with younger women more severely affected.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

The FDA has approved new labeling for Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium.

Top news of the day from across the health care landscape.

More than 4 in 10 women with asthma may develop chronic obstructive pulmonary disorder, but many risk factors are modifiable.

Patients with chronic obstructive pulmonary disease and who have other comorbid conditions are undertreated when hospitalized for exacerbations, study finds.

The results of a recent UK study reveal that psychological distress, whether considered low or moderate, can increase a patient’s risk for chronic obstructive pulmonary disease (COPD), arthritis, and cardiovascular disease (CVD).

The results of a recent UK study reveal that psychological distress, whether considered low or moderate, can increase a patient’s risk for chronic obstructive pulmonary disease, arthritis, and cardiovascular disease.

A new device intended to treat breathing difficulty associated with severe emphysema has been approved by the FDA.

Even though patients with advanced chronic obstructive pulmonary disease (COPD) can suffer from the same distressing symptoms as those with end-stage cancer, they are less likely to receive palliative care than those with other terminal illnesses.

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

In a recent study, researchers set out to identify the reasons why prescribers and pharmacists continue to prescribe NS β‐blockers despite the guidelines recommending against it.

Chronic obstructive pulmonary disease (COPD) patients may face various exacerbations that may affect their daily live with the disease through symptoms.

A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.